BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 9780839)

  • 1. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes.
    Ahrén B
    Bioessays; 1998 Aug; 20(8):642-51. PubMed ID: 9780839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
    Hui H; Yu R; Bousquet C; Perfetti R
    Endocrinology; 2002 Sep; 143(9):3529-39. PubMed ID: 12193567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin.
    Fehmann HC; Göke R; Göke B
    Mol Cell Endocrinol; 1992 May; 85(1-2):C39-44. PubMed ID: 1382025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
    Gromada J; Brock B; Schmitz O; Rorsman P
    Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is glucagon-like peptide 1 an incretin hormone?
    Nauck MA
    Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
    Byrne MM; Göke B
    Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of incretin hormones.
    Efendic S; Portwood N
    Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 13. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.
    Gromada J; Holst JJ; Rorsman P
    Pflugers Arch; 1998 Apr; 435(5):583-94. PubMed ID: 9479010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
    Baggio LL; Drucker DJ
    Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
    Thorens B; Waeber G
    Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 in NIDDM.
    Holst JJ
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S156-60. PubMed ID: 8894501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37).
    Holz GG; Leech CA; Heller RS; Castonguay M; Habener JF
    J Biol Chem; 1999 May; 274(20):14147-56. PubMed ID: 10318832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
    Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
    Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
    Nauck MA
    Acta Diabetol; 1998 Oct; 35(3):117-29. PubMed ID: 9840447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 and the gut.
    Thompson DG
    Gut; 2000 May; 46(5):591. PubMed ID: 10764696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.